about
Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis modelDifferential induction of functional IgG using the Plasmodium falciparum placental malaria vaccine candidate VAR2CSAAge at Mycobacterium bovis BCG Priming Has Limited Impact on Anti-Tuberculosis Immunity Boosted by Respiratory Mucosal AdHu5Ag85A Immunization in a Murine ModelCost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4.HspX vaccination and role in virulence in the guinea pig model of tuberculosis.Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner.The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in miceComparison of the predicted population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach.Recombinant BCG as a vaccine vehicle to protect against tuberculosis.Differential and site specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse.Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide LibraryThe development of a novel Mycobacterium-Escherichia coli shuttle vector system using pMyong2, a linear plasmid from Mycobacterium yongonense DSM 45126T.A High-Throughput Assay for Developing Inhibitors of PhoP, a Virulence Factor of Mycobacterium tuberculosisESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells.Mycolic acid-specific T cells protect against Mycobacterium tuberculosis infection in a humanized transgenic mouse modelProteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis-infected and culture filtrate protein-treated macrophages.Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses.Functional, biochemical and 3D studies of Mycobacterium tuberculosis protein peptides for an effective anti-tuberculosis vaccine.Development of a new tuberculosis vaccine: is there value in the mucosal approach?Comprehensive definition of human immunodominant CD8 antigens in tuberculosis.Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.Mycobacterium tuberculosis RpfE promotes simultaneous Th1- and Th17-type T-cell immunity via TLR4-dependent maturation of dendritic cells.A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells.Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
P2860
Q27309052-C4E0FF50-5C7B-41E1-8B9E-2E84BFD084E7Q27349502-D0CA3BED-4A36-480D-A48E-638ECEF377B7Q30375962-206BB906-55D1-4B3C-A8D3-3771B1094684Q33804506-CEDB8041-9A67-4FD0-9CA0-C25BA8EDB3D6Q33959963-5D485426-7540-4E6D-B6BA-56FA7763FABBQ34036411-C66C8AE9-1AD5-4E98-803F-E97141EE5E65Q34079170-DCF4DAA2-E472-4AF2-B120-49136B81B9D3Q34261521-A5B9C778-0BC1-4889-97FA-100272EECEB9Q34345342-DBE74FC4-0617-47C8-89E2-19D7CD3944ADQ34518560-761A9CBC-D7A1-4E4A-8E0D-272781A610C4Q34684829-54BF62FD-2A3B-42EA-B0DB-8E54C6077FB5Q34785626-053021B6-4511-468E-88C5-060EE500BE32Q35231090-3B22C215-F115-410F-8A66-FEC47358BEA6Q36164838-5A4F8D60-3DB0-4C92-9130-B09A9FEDB8B1Q36235479-3075725F-92F3-4AFA-8B28-098299EE4A36Q36479685-EB96CED5-D092-4E87-B989-893E0800F9A5Q36876961-213673F5-8CA0-4FA3-83E9-1F32BBC3C8EAQ36980878-3498DE1A-D70C-41D5-8EAD-017971438723Q37451207-0A0E85D6-ACE2-4252-A035-6D7F0327BFABQ37704447-3464C67C-1227-4617-BF82-1B44B5206543Q38085081-518019E4-130B-47CB-B16A-63ABCF7BC076Q38262258-1DBCA757-25B3-4785-A1D3-2B80F7B534A9Q38849398-8C12C212-7E8B-441A-9AE6-0F02F73B2BE4Q38886698-913A6E1E-191B-4E92-8E0C-8B273923F8BBQ39294350-BFD62D02-A6B0-4C7B-BED7-05F6EE445B86Q41021544-6BDD62C7-80DF-4699-87B9-F2D9C2BDCFFAQ42265160-2405CE10-1A68-456C-BF1F-7B7F458A9EEEQ50960529-F042C45A-59ED-448F-89E0-468E421D18B4Q52595182-C7EB5A04-9280-47C2-A44A-B22A0CC09D7CQ58765317-20230ABC-3B3E-4349-A6C8-61E3F6EE4054
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TB vaccines: current status and future perspectives.
@en
TB vaccines: current status and future perspectives.
@nl
type
label
TB vaccines: current status and future perspectives.
@en
TB vaccines: current status and future perspectives.
@nl
prefLabel
TB vaccines: current status and future perspectives.
@en
TB vaccines: current status and future perspectives.
@nl
P2093
P2860
P356
P1476
TB vaccines: current status and future perspectives.
@en
P2093
Claus Aagaard
Jes Dietrich
Mark Doherty
P2860
P304
P356
10.1038/ICB.2009.14
P577
2009-04-07T00:00:00Z